immunocore.com - IMCR Income before deduction of interest, taxes and amortization

Graphic logo of Immunocore Holdings (IMCR)

Immunocore Holdings plc (IMCR) margins are based on a combination of in-house laboratories and contract drug manufacturing. The EBITDA_Co valuation clearly demonstrates cash flow, where 0.00 reflects the baseline level of the metric. Immunocore Holdings plc (IMCR) strives for leadership in melanoma therapy through unique receptors, while the scaling of clinical trials relies on external vendors, necessitating strict control of production chains.

Profit before payment of interest, taxes and amortization: Immunocore Holdings plc (IMCR) for 11/23/2025 - 11/17/2026

Immunocore Holdings - analytical breakdowns and key metrics (IMCR)

- market value and analyst target forecast:
Analysis of all company metrics:immunocore.com - IMCR
Mass-produced product of Immunocore

For Immunocore Holdings plc (IMCR), investments in robotic T-cell receptor synthesis require a significant influx of liquidity. This metric captures the actual volume of cash generated by operations before taxes and debt obligations. By analyzing changes in EBITDA_Co, an investor can see the business's actual capacity for self-financing. Growth in this metric confirms the efficiency of laboratory automation, while a decline indicates a risk of capital shortage and the issuer's financial instability.

Competitors of Immunocore Holdings plc (IMCR)

ImmunityBio (IBRX) - Profit before interest, taxes and amortization|JANX: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization RCUS (Arcus Biosciences)|ZYME: Operating profit EBITDA|TNGX - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization iovance.com|Operating profit before deduction of amortization immatics.com (IMTX)|Profit before payment of interest, taxes and amortization Xencor Inc (XNCR)|Operating profit before deduction of amortization Compass Bio CMPX|Replimune Group Inc - Operating profit before deduction of amortization|Operating profit EBITDA Lyell Pharma LYEL|IPHA - Profit before payment of interest, taxes and amortization|PYXS (Pyxis Oncology) - Operating profit before amortization|cgen.com (CGEN) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization IO Biotech Corp (IOBT)|Operating profit before deduction of amortization STRO|INKT - Operating profit before depreciation charges|Operating profit before deduction of amortization HOWL (Werewolf Therapeutics)|Company profit before taxes, interest and amortization IMMX|Operating profit EBITDA ALXO (ALX Oncology)|cuebiopharma.com (CUE) - Profit before interest, taxes and amortization|PDS Biotechnology Corp - Operating profit EBITDA|Profit before interest, taxes and amortization Sonnet BioTherapeutics Holdings|MAIA Biotechnology (MAIA) - Profit before payment of interest, taxes and amortization|Liminatus Pharma - Income before deduction of interest, taxes and amortization|LVTX (Lava Tx) - Operating profit EBITDA|Operating profit EBITDA NextCure Inc|Profit before payment of interest, taxes and amortization leaptx.com (LPTX)|INTS: Profit before deduction of interest, taxes, depreciation and amortization|Sensei Biotherapeutics, Inc. - Operating profit before deduction of amortization|Theriva Biologics (TOVX) - Profit before interest, taxes and amortization|gritstonebio.com - Operating profit EBITDA|KA (Kineta) - Operating profit before amortization|NEXI: Operating profit EBITDA|Turnstone Biologics Corporation (TSBX) - Operating profit EBITDA|VCNX (vaccinex.com) - Operating profit EBITDA|HARP: Income before deduction of interest, taxes and amortization